Kan Yonemori
A breast and gynaecologic oncologist deeply involved in the early trastuzumab deruxtecan studies and in Japanese ADC development.
Kan Yonemori has been an investigator on DESTINY-Breast trials and early DXd studies, and leads medical oncology at the National Cancer Center Hospital across breast, gynaecologic, and sarcoma indications.
Pages like this
not linked directly; found by shared links- PersonNoboru Yamamoto
Shares National Cancer Center Hospital, Trastuzumab deruxtecan, Antibody-drug conjugate (ADC).
- PersonToshihiko Doi
Shares National Cancer Center Hospital, Trastuzumab deruxtecan, Antibody-drug conjugate (ADC).
- ProductTrastuzumab duocarmazine
Shares Trastuzumab deruxtecan, HER2-positive breast cancer, Antibody-drug conjugate (ADC).
- PersonJoohyuk Sohn
Shares DESTINY-Breast06: trastuzumab deruxtecan before any chemotherapy in hormone-receptor-positive, HER2-low or ultralow breast cancer, Trastuzumab deruxtecan, HER2-positive breast cancer, HR-positive / HER2-negative breast cancer.
- IdeaReduce the dose once the cancer responds: response-adapted de-escalation trials
Shares Trastuzumab deruxtecan, HER2-positive breast cancer, Antibody-drug conjugate (ADC).
- PersonSara A. Hurvitz
Shares Trastuzumab deruxtecan, HER2-positive breast cancer, Antibody-drug conjugate (ADC), HR-positive / HER2-negative breast cancer.
- PersonBob T. Li
Shares Trastuzumab deruxtecan, Antibody-drug conjugate (ADC).
- TrialDESTINY-Breast06
Shares DESTINY-Breast06: trastuzumab deruxtecan before any chemotherapy in hormone-receptor-positive, HER2-low or ultralow breast cancer, Trastuzumab deruxtecan, HR-positive / HER2-negative breast cancer.